Nykode Therapeutics AS announced the appointment of Klaus Edvardsen, M.D., Ph.D., as Chief Development Officer. The appointment will take effect on July 1, 2022. Klaus Edvardsen joins Nykode from CureVac where he held a similar role as Chief Development Officer.

Other previous roles include Senior Vice President and Head of Global Oncology Development of Merck KGaA, where he led early- and late-stage global oncology development. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca, where he was responsible for the overall development strategy for oncology and hematology programs. Klaus Edvardsen also held leadership roles at both GlaxoSmithKline and Genmab in medicines development within various therapeutic areas. Klaus Edvardsen holds a M.D. degree as well as a Ph.D. in cancer biology from University of Copenhagen.